The leading GLP-1 agents, say Ozempic and Wegovy, have patent protection in the U.S
chronic weight management coverage is more variable and often subject to prior authorization or BMI-based criteria
Patients who plateau on semaglutide monotherapy often respond dramatically to tirzepatide because it engages an entirely different hormonal mechanism
"If the cultural narrative becomes 'your body is only acceptable if medically modified', we risk increasing body dissatisfaction, perfectionism and appearance-related anxiety in younger generations." Such concerns, however, are only one way of looking at the Ozempic phenomenon
Medical Weight Loss Service Areas Across South, Central & North Florida Service Area Medical Weight Loss in Florida Our medical weight loss program proudly serves patients throughout South, Central, and North Florida with both in-office and secure telehealth consultations
95% CI, 0.850.91